State Street’s Vivos Therapeutics VVOS Stock Holding History

State Street’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.3K	Hold	24,922	–	–	﹤0.01%	4161
2026 Q1	$29.4K	Hold	24,922	–	–	﹤0.01%	4183
2025 Q4	$50.6K	Hold	24,922	–	–	﹤0.01%	4145
2025 Q3	$77.3K	Buy	24,922 +13,100	+111%	+$59.4K	﹤0.01%	4092
2025 Q2	$37.4K	Hold	11,822	–	–	﹤0.01%	4137
2025 Q1	$33.7K	Buy	+11,822	New	+$46.4K	﹤0.01%	4145
2023 Q4	–	Sell	-1,826	Closed	-$8.77K	–	4496
2023 Q3	$8.77K	Hold	1,826	–	–	﹤0.01%	4518
2023 Q2	$23.3K	Hold	1,826	–	–	﹤0.01%	4577
2023 Q1	$15.6K	Hold	1,826	–	–	﹤0.01%	4707
2022 Q4	$18.4K	Hold	1,826	–	–	﹤0.01%	4744
2022 Q3	$30K	Hold	1,826	–	–	﹤0.01%	4763
2022 Q2	$59K	Hold	1,826	–	–	﹤0.01%	4693
2022 Q1	$122K	Buy	1,826 +1,097	+150%	+$71.7K	﹤0.01%	4581
2021 Q4	$41K	Hold	729	–	–	﹤0.01%	4729
2021 Q3	$74K	Buy	+729	New	+$76.6K	﹤0.01%	4605

Other funds holding VVOS

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street's VVOS Position: Q2 2026 in Review

State Street held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 24,922 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4161.

State Street first reported a position in VVOS in Q3 2021 and has held it in 15 quarters since. The position peaked at $122K in Q1 2022. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

State Street held 24,922 shares of Vivos Therapeutics worth $11.3K as of Q2 2026.
State Street left its Vivos Therapeutics share count unchanged in Q2 2026.
Vivos Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4161 holding.
State Street first reported a position in Vivos Therapeutics in Q3 2021 and has held it in 15 quarters since.
State Street's Vivos Therapeutics position peaked at $122K in Q1 2022.
23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.